Hundreds of Facebook users furious as social media site goes down again two months after massive outage
FACEBOOK has gone down again for hundreds of users just months after a massive outage.
Frustrated users say they can't access the social media site and are being met with error messages.
Hundreds of complaints have been made in the last 24 hours, according to Down Detector.
Some users have taken to Twitter to complain about the apparent issues.
One said: "Ugh, #facebookdown more often than up. I have time to waste!"
Another wrote: "#Facebook is down. Now I'm forced to do actual work."
It comes two months after billions of people were blocked from using Facebook, Instagram and WhatsApp for seven hours after a major glitch.
The worldwide blackout was the site's worst global outage since 2008.
Facebook is yet to comment on the issue.
More to follow…
For the latest news on this story keep checking back at Sun Online.
Thesun.co.uk is your go to destination for the best celebrity news, football news, real-life stories, jaw-dropping pictures and must-see video.
Download our fantastic, new and improved free App for the best ever Sun Online experience. For iPhone click here, for Android click here.
Like us on Facebook at www.facebook.com/thesun and follow us from our main Twitter account at @TheSun.
India's Star Health choppy in debut after tepid IPO response
Shares of the country’s largest private health insurer fell as much as 6% at open before reversing course to gain 4.4%
Shares of India’s Star Health and Allied Insurance Co, backed by billionaire stock investor Rakesh Jhunjhunwala, see-sawed in their market debut on December 10 after a muted response to the initial public offering.
Shares of the country’s largest private health insurer fell as much as 6% at open before reversing course to gain 4.4%. They were trading 1.3% lower at 891.10 rupees, as of 0500 GMT.
At the day’s high of 940 rupees, the Chennai-based company was valued at 66.86 billion rupees ($883.69 million).
Star Health witnessed a tepid response to its initial public offering last week and had cut its IPO size to 64 billion rupees from 72.49 billion rupees.
"Considering the under subscription of the issue, the flatlisting of Star Health was expected. The financial performance was impacted in FY21, but long-term growth prospects of the industry remain quite promising," said Ajit Mishra, vice-president, research, Religare Broking.
Mr. Jhunjhunwala, who owns a near 15% stake in the insurer, did not put up any shares for sale in the IPO.
Star Health’s IPO failed to get fully subscribed, despite an extended subscription period signalling weak investor demand for India’s third-biggest listing this year.
($1 = 75.6600 Indian rupees)
‘Edible oil prices eased ₹8-10 a kg in 30 days’
Industry group sees further decline
Edible oil prices declined by ₹8-10 per kg in last one month mainly on the back of lower import duties and may fall by ₹3-4 per kg in coming months on higher domestic output of oilseeds and bearish trend in global markets, according to industry body SEA.
“The last few months have been harrowing for the Indian edible oil consumer largely on account of very high international prices of all oils viz. palm, soya and sunflower,” Solvent Extractors’ Association of India (SEA) president Atul Chaturvedi said.
SEA had advised its members before Diwali to reduce prices to the maximum extent possible, he said, adding that the Centre also reduced import duties on edible oils.
“We are happy to confirm all these actions have resulted in edible oil prices coming down by around ₹8-10 per kg in the last 30 days,” Mr. Chaturvedi said.
Celyad Oncology Stock Jumps 35% On $32.5 Mln Private Placement
Shares of Celyad Oncology SA (CYAD) jumped over 35% on Friday morning after the clinical-stage biotechnology company said it raised $32.5 million in a private placement with Fortress Investment Group.
CYAD is currently trading at $4.98, up $1.34 or 36.81%, on the Nasdaq.
Celyad said it has entered into a subscription agreement with an affiliate of Fortress Investment Group for the private placement of 6.5 million ordinary shares for gross proceeds of $32.5 million.
The company will issue the ordinary shares at $5.00 per share, which represents a 18.5% premium to the 30-day volume weighted average price.
The company intends to use the proceeds to fund research and development expenses, including the clinical development of its allogeneic CAR T candidates CYAD-101 and CYAD-211, to advance the current pipeline of preclinical CAR T candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA technology platform, as well as for working capital, other general corporate purposes, and the enhancement of the Company’s intellectual property.
Pfizer: Preliminary Data Shows Protection Against Omicron Improved With Third Dose Of Vaccine
Pfizer Inc. (PFE) and BioNTech SE (BNTX) reported results from an initial laboratory study showing that serum antibodies induced by the Pfizer-BioNTech COVID-19 vaccine neutralized the SARS-CoV-2 Omicron variant after three doses.
“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, CEO, Pfizer.
The companies noted that these results are preliminary, and they will continue to collect more laboratory data and evaluate real-world effectiveness.